

8:00AM Welcome by James Unger, Head of Corporate Finance

## Mid Cap Pharma

8:05AM  
**Experience on COVID-19 to date**  
**Mesoblast (MSB)**  
 Silviu Itescu,  
 Chief Executive Officer  
 Dr Fred Grossman,  
 Chief Medical Officer

8:30AM  
**Wet age-related macular degeneration - what's in the pipeline?**  
**Opthea (OPT)**  
 Megan Baldwin,  
 Managing Director & Chief Executive Officer

8:55AM  
**Zilusol commercialisation update**  
**Paradigm Biopharmaceuticals (PAR)**  
 Paul Rennie,  
 Chief Executive Officer

## Mid Cap Healthcare

9:20AM  
**Local and global expansion plans**  
**AFT Pharmaceuticals (AFP)**  
 Hartley Atkinson,  
 Chief Executive Officer  
 Malcolm Tubby,  
 Chief Financial Officer

9:45AM  
**Delivering improved outcomes - for COVID-19 and beyond**  
**Starpharma Holdings (SPL)**  
 Jackie Fairley,  
 Chief Executive Officer

10:10AM  
**EMVision's pilot clinical trial for its breakthrough portable brain scanner**  
**EMvision Medical Devices (EMV)**  
 Dr Ron Weinberger,  
 Managing Director  
 Scott Kirkland, Executive Director

## COVID-19

10:45AM  
**The global impact of COVID-19 on telehealth and mental health**  
**Doctor Care Anywhere (DOC)**  
 Bayju Thakar,  
 Chief Executive Officer  
 Kate Bunyan,  
 Chief Medical Officer

**Total Brain (TTB)**  
 Louis Gagnon,  
 Chief Executive Officer & Managing Director

11:15AM  
**The impact of COVID-19 on the hospital system**  
**Oneview Healthcare (ONE)**  
 James Fitter,  
 Chief Executive Officer  
**Royal Rehabilitation Group**  
 Matthew MacKay, Chief Executive Officer

**PainChek (PCK)**  
 Philip Daffas,  
 Chief Executive Officer  
 John Murray,  
 Non-Executive Director

11:45AM  
**Hunt for the COVID-19 vaccine**  
**Bioshares**  
 David Blake, Editor/Analyst & Co-founder of Bioshares

12:15PM  
**Australia's public health response to the COVID-19 pandemic, pre and post vaccine implementation**  
 Dr. Rob Grenfell, Director CSIRO Health & Biosecurity  
 Professor Jodie McVernon, Professor and Director of Epidemiology

## Wound

12:40PM  
**1Q21 company update**  
**Avita Therapeutics (AVH)**  
 Mike Perry,  
 Chief Executive Officer

1:05PM  
**Beyond just burns - a virtual tour of the new product manufacturing facility**  
**Polynovo (PNV)**  
 Paul Brennan,  
 Chief Executive Officer  
 Jan-Marcel Gielen,  
 Chief Financial Officer

1:30PM  
**CelGro: Returning function to paralysed limbs**  
**Orthocell (OCC)**  
 Paul Anderson,  
 Managing Director & Chief Executive Officer

1:55pm  
**A deep dive into the battle against biofilm**  
**Next Science (NXS)**  
 Judith Mitchell,  
 Managing Director  
 Dr. Thorsten M. Seyler,  
 MD & PhD

2:20PM  
**Clinical updates and insights: A discussion with TELA Bio's Chief Medical Officer**  
**Aroa Biosurgery (ARX)**  
 Brian Ward,  
 Chief Executive Officer  
 Dr Maarten Persenaire,  
 TELA Bio's Chief Medical Officer

2:50PM  
**Panel discussion: Trends in advanced wound care**  
**Aroa Biosurgery (ARX)**  
 Brian Ward, Chief Executive Officer  
 James Agnew, Chief Financial Officer  
**Polynovo (PNV)**  
 Paul Brennan, Chief Executive Officer  
 Jan-Marcel Gielen, Chief Financial Officer

3:50PM Wrap up by James Unger, Head of Corporate Finance

8:00AM Welcome by Anton Whitehead, Director of Equity Capital Markets

## Imaging Software

<p>8:05AM</p> <p><b>Visage AI Accelerator- a platform approach to AI in Radiology</b></p> <p><b>Pro Medicus (PME)</b> Dr Sam Hupert, Chief Executive Officer</p>	<p>8:30AM</p> <p><b>Resilience and case studies</b></p> <p><b>Volpara Health Technologies (VHT)</b> Ralph Highnam, Chief Executive Officer</p>	<p>8:55AM</p> <p><b>Commercialisation of XV technology</b></p> <p><b>4D Medical (4DX)</b> Andreas Fouras, Chief Executive Officer</p>	<p>9:20AM</p> <p><b>Commericalisation update</b></p> <p><b>Mach 7 Technologies (M7T)</b> Mike Lampron, Chief Executive Officer Jenni Pilcher, Chief Financial Officer</p>
--	--	---	---

## Small Cap Pharmaceuticals/ Diagnostics

<p>9:55AM</p> <p><b>Depth in products and pharma partnerships</b></p> <p><b>Immutep (IMM)</b> Marc Voigt, Chief Executive Officer</p>	<p>10:15AM</p> <p><b>Update from Genetic Signatures sales directors</b></p> <p><b>Genetic Signatures (GSS)</b> John Melki, Chief Executive Officer Jackson Jones, Director of Global Sales and Marketing</p>	<p>10:35AM</p> <p><b>Live demo of easy to use, award winning rapid tests for COVID-19 and others</b></p> <p><b>Atomo Diagnostics (AT1)</b> John Kelly, Chief Executive Officer Will Souter, Chief Financial Officer</p>	<p>10:55AM</p> <p><b>US commercialisation update</b></p> <p><b>Cyclopharm (CYC)</b> James McBrayer, Chief Executive Officer</p>
---	--	---	---

## Oncology and Immuno Oncology

<p>11:15AM</p> <p><b>Imugene program update</b></p> <p><b>Imugene (IMU)</b> Leslie Chong, Chief Executive Officer</p>	<p>11:35AM</p> <p><b>Commericalisation update</b></p> <p><b>Oncosil Medical (OSL)</b> Daniel Kenny, Chief Executive Officer</p>	<p>11:55AM</p> <p><b>Transitioning to a pivotal study</b></p> <p><b>Kazia Therapeutics (KZA)</b> James Garner, Chief Executive Officer</p>	<p>12:15pm</p> <p><b>Idiopathic Intracranial Hypertension (IIH) – A clinician’s perspective on this rapidly growing and costly disorder</b></p> <p><b>Invex Therapeutics (IXC)</b> Tom Duthy, Executive Director</p>
---	---	--	--

## Mid Cap Devices

<p>12:55PM</p> <p><b>Pentrox: Unlocking our potential in Europe</b></p> <p><b>Medical Developments International (MVP)</b> Brent MacGregor, Chief Executive Officer</p>	<p>1:20PM</p> <p><b>Business update</b></p> <p><b>Nanosonics (NAN)</b> Michael Kavanagh, Chief Executive Officer McGregor Grant, Chief Financial Officer</p>	<p>1:45PM</p> <p><b>Procedure demonstration of Imricor’s novel MRI compatible catheters</b></p> <p><b>Imricor Medical Systems (IMR)</b> Steve Wedan, Chief Executive Officer</p>	<p>2:10PM</p> <p><b>Focus on ongoing sales progress and demand, impact of new facility and clarity on guidance</b></p> <p><b>Cleanspace (CSX)</b> Dr Alex Birrell, Chief Executive Officer Elizabeth Harvey, Chief Financial Officer</p>	<p>2:35PM</p> <p><b>Targeting radiopharmaceuticals: Focus on Telix’s therapeutic progress</b></p> <p><b>Telix Pharmaceuticals (TLX)</b> Dr. Christian Behrenbruch, Chief Executive Officer Dr. David Cade, Chief Business Officer</p>
---	--	--	--	---

3:00PM Wrap up by James Unger, Head of Corporate Finance